[1]赖伟玲,谢才有.丹参注射液联合新活素对心衰急性发作期患者血液流变学及心功能的影响[J].医学信息,2025,38(07):133-136.[doi:10.3969/j.issn.1006-1959.2025.07.026]
　LAI Weiling,XIE Caiyou.Effect of Danshen Injection Combined with rhBNP on Hemorheology and Cardiac Function in Patients with Acute Attack of Heart Failure[J].Journal of Medical Information,2025,38(07):133-136.[doi:10.3969/j.issn.1006-1959.2025.07.026]
点击复制

丹参注射液联合新活素对心衰急性发作期患者血液流变学及心功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年07期
页码:
133-136
栏目:
论著
出版日期:
2025-04-01

文章信息/Info

Title:
Effect of Danshen Injection Combined with rhBNP on Hemorheology and Cardiac Function in Patients with Acute Attack of Heart Failure
文章编号:
1006-1959（2025）07-0133-04
作者:
赖伟玲1; 谢才有2
1.龙南市第二人民医院中西医结合内科，江西 龙南 341700；2.龙南市第一人民医院重症医学科，江西 龙南 341700
Author(s):
LAI Weiling1;  XIE Caiyou2
1.Internal Medicine of Integrated Medicine, Longnan Second People’s Hospital, Longnan 341700, Jiangxi, China;2.Department of Critical Medicine, Longnan First People’s Hospital, Longnan 341700, Jiangxi, China
关键词:
丹参注射液; 新活素; 心衰; 急性发作期; 血液流变学; 心功能
Keywords:
Danshen injection;  rhBNP;  Heart failure;  Acute attack;  Hemorheology;  Cardiac function
分类号:
R541.6；R259
DOI:
10.3969/j.issn.1006-1959.2025.07.026
文献标志码:
A
摘要:
目的 观察丹参注射液联合新活素对心衰急性发作期患者血液流变学及心功能的影响。方法 选取2021年1月-2023年9月在龙南市第二人民医院诊治的60例心衰急性发作期患者为研究对象，采用随机数字表法分为对照组和观察组，各组30例。对照组采用新活素治疗，观察组在对照组基础上给予丹参注射液治疗，比较两组临床疗效、心功能指标、血流动力学指标、不良反应发生率。结果 观察组治疗总有效率高于对照组（P＜0.05）；观察组治疗后LVEF高于对照组，LVESV、LVEDV低于对照组（P＜0.05）；两组PV、FIB、HBV均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为10.00%，与对照组的6.67%比较，差异无统计学意义（P＞0.05）。结论 丹参注射液联合新活素治疗心衰急性发作期效果确切，可改善血液流变学、心功能，提高治疗总有效率，且无显著不良反应，具有临床应用优势。
Abstract:
Objective To observe the effect of Danshen injection combined with rhBNP on hemorheology and cardiac function in patients with acute attack of heart failure. Methods From January 2021 to September 2023, a total of 60 patients diagnosed with acute exacerbation of heart failure at Longnan Second People’s Hospital were enrolled in this study. The patients were randomly assigned to either a control group or an observation group (30 patients each) using a random number table. The control group received recombinant human B-type natriuretic peptide (rhBNP) therapy, while the observation group was treated with Danshen injection in addition to rhBNP. Clinical efficacy, cardiac function parameters, hemodynamic indices, and the incidence of adverse reactions were compared between the two groups. Results The total treatment efficacy rate in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the observation group demonstrated a higher LVEF and lower LVESV and LVEDV than the control group (P<0.05). Additionally, PV, FIB, and HBV levels were significantly reduced in both groups, with the observation group showing lower values than the control group (P<0.05). The incidence of adverse reactions was 10.00% in the observation group and 6.67% in the control group, with no statistically significant difference (P>0.05). Conclusion The combination of Danshen injection and rhBNP demonstrates superior efficacy in treating acute heart failure exacerbations, improving cardiac function and hemodynamics without significantly increasing adverse reactions.

参考文献/References:

[1]曹磊,掌瑜.急性心肌梗死患者的临床特征及心力衰竭相关因素分析[J].临床合理用药杂志,2019,12(34):16-18.[2]张红兵,蒋崇慧,杨鹏,等.强离子隙对急性心肌梗死发生急性心力衰竭的预测价值[J].中华急诊医学杂志,2019,28(1):79-83.[3]金九美.左西孟旦对慢性收缩性心衰患者急性发作的近期疗效及安全性研究[D].石家庄:河北医科大学,2018.[4]张亮,李海林.左西孟旦对顽固性心力衰竭患者心功能的影响[J].中国中西医结合急救杂志,2019,26(3):307-309.[5]于潇,杨汇娟.左心室射血分数联合血管生成素2对慢性心力衰竭患者预后的评估价值[J].重庆医科大学学报,2018,43(3):372-376.[6]中华医学会心血管病学分会,中国心肌炎心肌病协作组.中国扩张型心肌病诊断和治疗指南[J].临床心血管病杂志,2018,34(5):421-434.[7]]Lam CSP,Li YH,Bayes-Genis A,et al.The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure[J].J Chin Med Assoc,2019,82(6):447-451.[8]张相杰,黄文平,许有凡.沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑、炎症因子的影响[J].实用医学杂志,2019,35(5):795-799.[9]Juguet W,Fard D,Faivre L,et al.Levosimendan plus dobutamine in acute decompensated heart failure refractory to dobutamine [J].J Clin Med,2020,9(11):3605.[10]张学平,刘志强,田现伟.左西孟旦联合常规抗心力衰竭药物治疗顽固性心力衰竭疗效评价[J].中国药物与临床,2021,21(12):2119-2120.[11]卜荣生,杜心清,吴淳淳.新活素联合左卡尼丁治疗顽固性心力衰竭临床研究[J].浙江临床医学,2018,20(5):844-846.[12]李申海,王艳春,李文杰.重组人脑钠利肽治疗急性失代偿性心衰20例[J].辽宁中医药大学学报,2007,9(3):116-117.[13]谭碧松.黄芪注射液联合复方丹参注射液治疗老年慢性充血性心力衰竭急性发作疗效观察[J].现代中西医结合杂志,2017,26(7):734-736.[14]牛洁婷,马育霞,李艳光,等.左西孟旦联合新活素治疗顽固性心力衰竭的临床疗效[J].中国老年学杂志,2021,41(24):5489-549.[15]张凤云,徐晤,王向东,等.新活素对急性心肌梗死后心力衰竭的疗效及安全性分析[J].医学研究杂志,2019,48(6):50-54.[16]王艳丽,王艳萍,马金波,等.芪苈强心胶囊辅治扩张型心肌病合并慢性心力衰竭的疗效及对神经内分泌因子、炎性因子及心室重构的影响[J].解放军医药杂志,2021,33(2):84-88.[17]李辉,李彬,李文香.参鹿宁心汤治疗顽固性心力衰竭的疗效及对患者心肌重塑、心功能的影响[J].环球中医药,2022,15(2):338-341.[18]任惠锋,周宏伟.生脉注射液联合丹参川芎嗪治疗左心室射血分数降低性心力衰竭疗效及对红细胞体积分布宽度、B型利钠肽的影响[J].现代中西医结合杂志,2018,27(25):2801-2804.[19]占钻,曹春水,江娟,等.复方丹参注射液对大鼠心肺复苏后凝血功能及血液流变学的影响[J].重庆医学,2019,48(15):2524-2527.[20]王亚莉,胡慧英,张洪珍,等.新活素对慢性肺源性心脏病急性加重期患者心肺功能的影响[J].中国分子心脏病学杂志,2021,21(3):3973-3976.[21]殷晓艳.生脉注射液联合重组人脑利钠肽治疗急性心力衰竭的临床研究[J].现代药物与临床,2018,33(3):483-486.

相似文献/References:

[1]宋昆鹏,石海莉,郭素萍,等.新活素治疗低心排血量综合征的效果观察[J].医学信息,2019,32(20):136.[doi:10.3969/j.issn.1006-1959.2019.20.042]
　SONG Kun-peng,SHI Hai-li,GUO Su-ping,et al.Effect of Neonatal on Low Cardiac Output Syndrome[J].Journal of Medical Information,2019,32(07):136.[doi:10.3969/j.issn.1006-1959.2019.20.042]
[2]龙海成,郭 华,胡雪平.新活素联合地高辛治疗慢性心衰急性加重期的疗效[J].医学信息,2023,36(24):76.[doi:10.3969/j.issn.1006-1959.2023.24.015]
　LONG Hai-cheng,GUO Hua,HU Xue-ping.Curative Effect of rhBNP Combined with Digoxin in the Treatment of Acute Exacerbation of Chronic Heart Failure[J].Journal of Medical Information,2023,36(07):76.[doi:10.3969/j.issn.1006-1959.2023.24.015]

更新日期/Last Update: 1900-01-01